Summary
Using primary patient AML samples, PDX mouse models, single-cell/bulk omics profiling and integrative data analysis A06 will identify the underlying intra- and extra-cellular regulators and regulatory networks responsible for the switch from dormancy to the actively proliferating state of LSCs. Given the reversibility of the plastic phenotype, novel therapeutic approaches to release resistant LSCs from their protective bone marrow environment in order to convert them into treatment-responsive cells shall be investigated by reverse genetics in PDX models in vivo.

Lead Investigator
Dr. Junyan Lu
Multi-omics and Precision Oncology, Medical Faculty, Heidelberg University

Lead Investigator
Prof. Dr. Irmela Jeremias
Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital

Team:
Cell-Intrinsic Factors (Area A)











